Guardian Pharmacy Services
GRDN
40.68
-0.52
-1.26%
Guardian Pharmacy Services
US · GRDN
#2584 by market cap
Listed 2024
40.68
-0.52
-1.26%
Live - 5344 symbols - heartbeat 124s ago
· 2026-10-08 07:14
Pre-market
40.68
0.00%
After-hours
40.68
0.00%
- Market cap
- 2.58B
- P/E (TTM)i
- 39.12
- P/Bi
- 10.49
- EPSi
- 0.78
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on GRDN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 12.43, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +17.93% YoY
Margins
- Gross margin
- 20.21%
- Operating margin
- 5.02%
- Net margin
- 3.40%
Key ratios & quality
- PEG ratioi
- 3.37
- Altman Z-Scorei
- 12.43
PEG uses trailing P/E against the 3-year net income growth rate (11.59%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 600.37M | 698.29M | 735.96M | 792.07M | 908.91M | 1.05B | 1.23B | 1.45B |
| Gross profit | 123.03M | 143.46M | 147.00M | 161.27M | 185.87M | 208.31M | 244.37M | 292.72M |
| Selling & admin expenses | 87.85M | 97.56M | 102.54M | 131.12M | 133.88M | 167.36M | 307.29M | 220.02M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 26.13M | 35.32M | 32.95M | 30.15M | 51.99M | 40.95M | -62.92M | 72.70M |
| Pretax profit | 23.27M | 31.37M | 29.66M | 28.33M | 49.66M | 37.72M | -66.48M | 73.42M |
| Tax | -- | -- | -- | -- | -- | 0 | 4.56M | 24.47M |
| Net profit | 23.27M | 31.37M | 29.66M | 28.33M | 49.66M | 37.72M | -71.03M | 48.96M |
| Basic EPS | 0 | 0 | 0 | 0 | 1 | 0 | -2 | 1 |
| Diluted EPS | 0.24 | 0.36 | 0.33 | 0.27 | 0.58 | 0.00 | -1.77 | 0.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 329.31M | 344.33M | 377.43M | 397.62M | 336.60M | 351.77M |
| Gross profit | 64.35M | 68.15M | 74.72M | 85.50M | 76.31M | 80.04M |
| Selling & admin expenses | 51.34M | 55.57M | 58.37M | 54.74M | 58.63M | 59.40M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 13.01M | 12.58M | 16.35M | 30.76M | 17.68M | 20.64M |
| Pretax profit | 13.11M | 12.59M | 16.63M | 31.10M | 18.29M | 29.79M |
| Tax | 3.83M | 3.76M | 7.04M | 9.83M | 4.75M | 7.67M |
| Net profit | 9.27M | 8.83M | 9.59M | 21.27M | 13.54M | 22.12M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.15 | 0.14 | 0.15 | 0.33 | 0.21 | 0.34 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 81.23M | 90.08M | 93.82M | 111.87M | 120.00M | 129.61M | 151.99M | 221.63M |
| Cash & ST investments | 2.25M | 275.00K | 6.45M | 15.01M | 607.00K | 752.00K | 4.66M | 65.62M |
| Inventory | 27.54M | 30.94M | 31.93M | 33.09M | 41.44M | 36.73M | 40.55M | 43.36M |
| Total assets | 181.81M | 196.52M | 217.87M | 235.85M | 256.11M | 271.17M | 320.81M | 412.66M |
| Total current liabilities | 65.27M | 90.19M | 86.35M | 111.54M | 112.01M | 138.02M | 144.12M | 160.70M |
| Short-term debt | 4.99M | 19.87M | 12.56M | 9.62M | 13.50M | 19.21M | 6.84M | 7.15M |
| Long-term debt | 36.37M | 33.66M | 30.74M | 26.99M | 22.97M | 18.99M | -- | -- |
| Total liabilities | 113,798,000.00 | 139,472,000.00 | 150,798,000.00 | 182,532,000.00 | 180,185,000.00 | 211,306,000.00 | 170,834,000.00 | 194,734,000.00 |
| Total equity | 68.01M | 57.04M | 67.07M | 53.32M | 75.93M | 59.86M | 149.98M | 217.92M |
| Retained earnings | -- | -- | -- | -- | -- | -- | 17.12M | 66.34M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 166.04M | 170.46M | 198.28M | 221.63M | 235.18M | 254.67M |
| Cash & ST investments | 14.00M | 18.82M | 36.49M | 65.62M | 64.89M | 89.81M |
| Inventory | 43.43M | 44.16M | 47.86M | 43.36M | 47.16M | 50.44M |
| Total assets | 334.00M | 356.33M | 390.04M | 412.66M | 426.94M | 443.58M |
| Total current liabilities | 145.30M | 143.99M | 161.95M | 160.70M | 160.54M | 154.04M |
| Short-term debt | 6.67M | 7.18M | 6.72M | 7.15M | 7.22M | 7.38M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 170,781,000.00 | 176,663,000.00 | 194,540,000.00 | 194,734,000.00 | 194,517,000.00 | 185,936,000.00 |
| Total equity | 163.22M | 179.67M | 195.50M | 217.92M | 232.42M | 257.64M |
| Retained earnings | 26.57M | 35.60M | 45.42M | 66.34M | 79.64M | 101.51M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 43.68M | 56.16M | 52.61M | 58.50M | 48.52M | 70.82M | 57.96M | 100.26M |
| Depreciation & amortization | 13.13M | 15.85M | 17.26M | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| Free cash flow | 33.67M | 41.62M | 44.27M | 49.22M | 31.75M | 56.26M | 41.59M | 80.71M |
| Dividends paid | -27.99M | -34.32M | -10.82M | -17.36M | -30.80M | -38.42M | -35.75M | 0 |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | 0 | 64.61M | 0 |
| Ending cash balance | 2.25M | 275.00K | 6.45M | 15.01M | 607.00K | 752.00K | 4.66M | 65.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 17.55M | 19.94M | 28.17M | 34.60M | 6.06M | 30.03M |
| Depreciation & amortization | 5.27M | 5.49M | 5.84M | 5.74M | 5.98M | 5.81M |
| Free cash flow | 11.75M | 15.63M | 22.96M | 30.37M | 1.04M | 25.41M |
| Dividends paid | -- | -- | -- | 0 | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 0 | 0 |
| Ending cash balance | 14.00M | 18.82M | 36.49M | 65.62M | 64.89M | 89.81M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 43.13 | 67.97 | 58.28 | 52.28 | 106.28 | 67.39 | -128.80 | 28.25 |
| ROA %i | 8.07 | 11.50 | 9.63 | 7.19 | 14.40 | 9.07 | -37.18 | 13.42 |
| ROIC %i | 20.66 | 28.38 | 23.34 | 20.40 | 42.38 | 27.57 | -82.14 | 23.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | 65.83 | 57.21 | 17.72 | 11.60 |
| EBIT margin %i | 4.19 | 4.82 | 4.32 | 3.78 | 5.68 | 3.88 | -5.14 | 5.11 |
| FCF / sales %i | 5.61 | 5.96 | 6.02 | 6.21 | 3.49 | 5.38 | 3.39 | 5.57 |
| Current ratioi | 1.24 | 1.00 | 1.09 | 1.00 | 1.07 | 0.94 | 1.05 | 1.38 |
| Quick ratioi | 0.76 | 0.60 | 0.64 | 0.63 | 0.61 | 0.57 | 0.71 | 1.04 |
| Debt / assetsi | 24.04 | 29.07 | 27.01 | 21.38 | 22.18 | 22.50 | 9.39 | 9.00 |
| LT debt / equityi | 113.78 | 127.02 | 120.28 | 170.56 | 101.36 | 148.16 | 16.33 | 14.58 |
| Interest coveragei | 13.25 | 14.94 | 14.76 | 18.30 | 26.78 | 14.19 | -19.28 | 111.41 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 9.68 | 9.18 | 12.44 | 15.75 | 16.81 |
| Net income CAGR (3Y) %i | -- | -- | -- | 3.59 | 17.66 | 6.22 | -- | 11.59 |
| FCF CAGR (3Y) %i | -- | -- | -- | 13.49 | -8.63 | 8.32 | -5.46 | 36.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -64.45 | -97.70 | 25.85 | 28.25 | 28.15 | 31.75 |
| ROA %i | -30.12 | -27.69 | 10.90 | 13.42 | 13.95 | 16.48 |
| ROIC %i | -53.43 | -60.73 | 19.44 | 23.89 | 24.19 | 27.41 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.51 | -4.67 | 4.28 | 5.11 | 5.44 | 6.59 |
| FCF / sales %i | 3.77 | 2.86 | 4.91 | 5.57 | 4.81 | 5.45 |
| Current ratioi | 1.14 | 1.18 | 1.22 | 1.38 | 1.46 | 1.65 |
| Quick ratioi | 0.77 | 0.78 | 0.88 | 1.04 | 1.10 | 1.26 |
| Debt / assetsi | 8.52 | 9.46 | 8.74 | 9.00 | 8.64 | 7.94 |
| LT debt / equityi | 13.96 | 15.64 | 14.89 | 14.58 | 13.43 | 11.34 |
| Interest coveragei | -21.54 | -34.62 | 64.43 | 111.41 | 122.12 | 152.85 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Sales of pharmaceutical and medical products100.00%
Quote time 2026-10-08 07:14:49 · For reference only, not investment advice and not tailored to your situation.